公开(公告)号：US20160317572A1

公开(公告)日：2016-11-03

申请号：US15210226

申请日：2016-07-14

Applicant: Relypsa, Inc.

Inventor： Dominique Charmot ,  Han-Ting Chang ,  Gerrit Klaerner ,  Jerry M. Buysse ,  Mingjun Liu

IPC: A61K31/78 ,  A61K31/795 ,  C08F120/06 ,  A61K31/80 ,  A61K31/785 ,  C08F128/02 ,  A61K45/06 ,  A61K9/14

CPC classification number: A61K31/78 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/74 ,  A61K31/785 ,  A61K31/795 ,  A61K31/80 ,  A61K45/06 ,  C08F120/06 ,  C08F128/02 ,  Y10S514/838 ,  Y10S514/869 ,  Y10S514/87 ,  Y10S514/893

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

公开(公告)号：US09186404B2

公开(公告)日：2015-11-17

申请号：US12475627

申请日：2009-06-01

Applicant: Alan John Nimmo ,  Robert Vink

Inventor： Alan John Nimmo ,  Robert Vink

IPC: A61K31/455 ,  A61K31/44 ,  A61K31/496 ,  A61K31/166 ,  A61K45/06 ,  A61K33/06 ,  A61K33/14

CPC classification number: A61K33/06 ,  A61K31/166 ,  A61K31/44 ,  A61K31/455 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61K33/14 ,  A61K45/06 ,  Y10S514/87 ,  A61K31/00 ,  A61K2300/00

Abstract: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.

Abstract translation: 脑，脊髓和神经损伤的治疗包括使用任选与镁化合物组合的P物质受体拮抗剂。 还提供了用于该治疗的制剂，其包含物质P受体拮抗剂和镁化合物。

公开(公告)号：US08980952B2

公开(公告)日：2015-03-17

申请号：US11359946

申请日：2006-02-22

Applicant: J. Marc Simard ,  Mingkui Chen

Inventor： J. Marc Simard ,  Mingkui Chen

IPC: A61K31/18 ,  A61K31/64 ,  A61K31/435 ,  A61K31/198 ,  A61K31/415 ,  A61K31/17 ,  A61K31/00 ,  A61K31/175 ,  A61K31/365 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/56 ,  A61K31/70 ,  A61K31/7048 ,  B01J19/00 ,  B32B37/12 ,  C07K14/705 ,  G01N27/447 ,  G01N33/68 ,  B29L31/00

CPC classification number: A61K31/64 ,  A61K9/0019 ,  A61K31/00 ,  A61K31/17 ,  A61K31/175 ,  A61K31/365 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/56 ,  A61K31/565 ,  A61K31/566 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7048 ,  B01J19/0093 ,  B29L2031/756 ,  B32B37/1292 ,  C07K14/705 ,  G01N27/44791 ,  G01N33/6872 ,  G01N2500/04 ,  Y10S514/87

Abstract: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.

Abstract translation: 本发明涉及影响神经组织（包括神经系统内的神经元，神经胶质细胞和血管）的NCCa-ATP通道的治疗化合物，治疗方法和试剂盒及其使用方法。 NCCa-ATP通道在损伤如缺血后在神经组织中新表达，并且被磺酰脲受体SUR1调节，被磺酰脲化合物例如格列本脲和甲苯磺丁脲抑制，并被二氮嗪打开。 包括SUR1拮抗剂在内的NCCa-ATP通道的拮抗剂可用于预防，减少和治疗包括星形胶质细胞，神经元和毛细血管内皮细胞在内的损伤或患病神经组织，这是由于缺血，组织创伤，脑肿胀和 增加组织压力，或其他形式的脑或脊髓疾病或损伤。 NCCa-ATP通道的激动剂可用于治疗神经组织，其中需要诸如胶质胶囊的组织的损伤或破坏。

公开(公告)号：US20140235564A1

公开(公告)日：2014-08-21

申请号：US14184947

申请日：2014-02-20

Applicant: J. Marc Simard ,  Mingkui Chen

Inventor： J. Marc Simard ,  Mingkui Chen

IPC: A61K31/7076 ,  A61K31/4453 ,  A61K31/4015 ,  A61K31/195 ,  A61K31/403 ,  A61K31/18 ,  A61K31/197

CPC classification number: G01N33/5058 ,  A61K31/00 ,  A61K31/175 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/4453 ,  A61K31/64 ,  A61K31/7076 ,  A61K49/0008 ,  B01J19/0093 ,  B29L2031/756 ,  B32B37/1292 ,  C07K14/705 ,  C12N5/0622 ,  G01N33/5076 ,  G01N33/6872 ,  G01N2500/04 ,  Y10S514/87

Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.

Abstract translation: 描述了包含新型Ca 2+活化的[ATP] i敏感性非特异性阳离子（NCCa-ATP）通道的组合物。 该通道存在于哺乳动物神经细胞中，表现出不同的腺嘌呤核苷酸的阻断灵敏度，并被亚微摩尔[Ca] i激活。 NCCa-ATP通道在ATP耗尽的条件下被激活，这导致严重的细胞去极化，随后是细胞肿胀。 NCCa-ATP通道受磺酰脲受体调节，被磺酰脲类化合物格列本脲和甲苯磺丁脲抑制。 描述了使用包含NCCa-ATP通道的组合物筛选阻断通道的化合物和使用这种拮抗剂作为治疗剂以防止脑肿胀和损伤的方法。 此外，描述了使用包含Kir2.3通道的组合物筛选开放通道的化合物的方法，以及使用这种拮抗剂作为治疗剂以防止脑肿胀和损伤的方法。

公开(公告)号：US08475780B2

公开(公告)日：2013-07-02

申请号：US13015134

申请日：2011-01-27

Applicant: Dominique Charmot ,  Han-Ting Chang ,  Gerrit Klaerner ,  Jerry M. Buysse ,  Mingjun Liu

Inventor： Dominique Charmot ,  Han-Ting Chang ,  Gerrit Klaerner ,  Jerry M. Buysse ,  Mingjun Liu

IPC: A61K31/74

CPC classification number: A61K31/78 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/74 ,  A61K31/785 ,  A61K31/795 ,  A61K31/80 ,  A61K45/06 ,  C08F120/06 ,  C08F128/02 ,  Y10S514/838 ,  Y10S514/869 ,  Y10S514/87 ,  Y10S514/893

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

公开(公告)号：US08287847B2

公开(公告)日：2012-10-16

申请号：US12055765

申请日：2008-03-26

Applicant: Dominique Charmot ,  Han-Ting Chang ,  Mingjun Liu ,  Gerrit Klaerner

Inventor： Dominique Charmot ,  Han-Ting Chang ,  Mingjun Liu ,  Gerrit Klaerner

IPC: A61K31/74

CPC classification number: A61K31/78 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/74 ,  A61K31/785 ,  A61K31/795 ,  A61K31/80 ,  A61K45/06 ,  C08F120/06 ,  C08F128/02 ,  Y10S514/838 ,  Y10S514/869 ,  Y10S514/87 ,  Y10S514/893

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

公开(公告)号：US20120237449A1

公开(公告)日：2012-09-20

申请号：US13483824

申请日：2012-05-30

Applicant: J. Marc Simard ,  Mingkui Chen

Inventor： J. Marc Simard ,  Mingkui Chen

IPC: A61K31/18 ,  A61K31/197 ,  A61K31/195 ,  A61K31/4439 ,  A61K31/403 ,  A61K31/4015 ,  A61K31/7076 ,  A61K49/00 ,  A61K31/404 ,  A61P25/00 ,  A61P29/00 ,  C07K14/47 ,  G01N33/566 ,  C12Q1/02 ,  G01N33/68 ,  C12N5/079 ,  A61K31/451

CPC classification number: G01N33/5058 ,  A61K31/00 ,  A61K31/175 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/4453 ,  A61K31/64 ,  A61K31/7076 ,  A61K49/0008 ,  B01J19/0093 ,  B29L2031/756 ,  B32B37/1292 ,  C07K14/705 ,  C12N5/0622 ,  G01N33/5076 ,  G01N33/6872 ,  G01N2500/04 ,  Y10S514/87

Abstract: A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NCCa-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.

Abstract translation: 描述了包含新型Ca 2+活化的[ATP] i敏感性非特异性阳离子（NCCa-ATP）通道的组合物。 该通道存在于哺乳动物神经细胞中，表现出不同的腺嘌呤核苷酸的阻断灵敏度，并被亚微摩尔[Ca] i激活。 NCCa-ATP通道在ATP耗尽的条件下被激活，这导致严重的细胞去极化，随后是细胞肿胀。 NCCa-ATP通道受磺酰脲受体调节，被磺酰脲类化合物格列本脲和甲苯磺丁脲抑制。 描述了使用包含NCCa-ATP通道的组合物筛选阻断通道的化合物和使用这种拮抗剂作为治疗剂以防止脑肿胀和损伤的方法。 此外，描述了使用包含Kir2.3通道的组合物筛选开放通道的化合物的方法，以及使用这种拮抗剂作为治疗剂以防止脑肿胀和损伤的方法。

公开(公告)号：US20110033505A1

公开(公告)日：2011-02-10

申请号：US12857264

申请日：2010-08-16

Applicant: Dominique Charmot ,  Han-Ting Chang ,  Mingjun Liu ,  Futian Liu ,  Gerrit Klaerner

Inventor： Dominique Charmot ,  Han-Ting Chang ,  Mingjun Liu ,  Futian Liu ,  Gerrit Klaerner

IPC: A61K9/00 ,  A61K31/663 ,  A61K31/662 ,  A61K31/185 ,  A61K31/194 ,  A61K31/19 ,  A61P9/12 ,  A61P7/10

CPC classification number: A61K31/78 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/5026 ,  A61K9/5031 ,  A61K31/74 ,  A61K31/785 ,  A61K31/795 ,  A61K31/80 ,  A61K45/06 ,  C08F120/06 ,  C08F128/02 ,  Y10S514/838 ,  Y10S514/869 ,  Y10S514/87 ,  Y10S514/893

Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Abstract translation: 本发明提供了用于治疗离子失衡的方法和组合物。 特别地，本发明提供了包含钠结合聚合物及其药物组合物的组合物。 本文公开了用于治疗和/或预防益处的聚合物和药物组合物的使用方法。 这些方法的实例包括治疗高血压，慢性心力衰竭，终末期肾病，肝硬化，慢性肾功能不全，流体过载或钠过载。

公开(公告)号：US07816374B2

公开(公告)日：2010-10-19

申请号：US12151735

申请日：2008-05-08

Applicant: Gerald J. Gleich ,  Loren W. Hunt, Jr.

Inventor： Gerald J. Gleich ,  Loren W. Hunt, Jr.

IPC: A61K31/47 ,  A61K31/445

CPC classification number: A61K31/4453 ,  A61K31/167 ,  A61K31/24 ,  A61K31/245 ,  A61K31/445 ,  A61K31/47 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/87

Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

Abstract translation: 通过局部施用需要这种治疗的哺乳动物，提供有效量的局部麻醉剂如利多卡因或其药学上可接受的盐来治疗嗜中性粒细胞相关性肺疾病如慢性阻塞性肺疾病的治疗方法 。

公开(公告)号：US20090054485A1

公开(公告)日：2009-02-26

申请号：US12151735

申请日：2008-05-08

Applicant: Gerald J. Gleich ,  Loren W. Hunt, JR.

Inventor： Gerald J. Gleich ,  Loren W. Hunt, JR.

IPC: A61K31/445 ,  A61K31/24 ,  A61P11/00

CPC classification number: A61K31/4453 ,  A61K31/167 ,  A61K31/24 ,  A61K31/245 ,  A61K31/445 ,  A61K31/47 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/87

Abstract: A therapeutic method is provided to treat neutrophil-associated pulmonary diseases, such as chronic obstructive pulmonary disease, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.

Abstract translation: 通过局部施用需要这种治疗的哺乳动物，提供有效量的局部麻醉剂如利多卡因或其药学上可接受的盐来治疗嗜中性粒细胞相关性肺疾病如慢性阻塞性肺疾病的治疗方法 。